| |
|
Leadership - Management
- Christopher K. Mirabelli, Ph.D.
Interim Chief Executive Officer
Dr. Mirabelli has been a Managing Director at HealthCare Ventures, LLC since 2000. In addition to serving as Chairman of the Board of Proteostasis Therapeutics, Inc., Dr. Mirabelli currently serves as a member of the Board of Directors of Anexon, Inc., Ascent Therapeutics Corporation, DecImmune Therapeutics, Inc., Galleon Pharmaceuticals, Inc., Synovex Corporation, Theraclone Sciences, Trevena, Inc., and Visionary Therapeutics Corporation. Previously, from 1993 through 1999, Dr. Mirabelli served as Chairman of the Board and Chief Executive Officer of LeukoSite, Inc. until its merger with Millennium Pharmaceuticals in December 1999; Dr. Mirabelli presided over the integration of LeukoSite into Millennium as President of Pharmaceutical R&D and a member of the Company’s Board of Directors until mid-2000. Dr. Mirabelli was a founder of Isis Pharmaceuticals, Inc., where he served in a number of senior executive research and development positions from 1989 to 1993. He was a member of SmithKline and French Laboratories R&D Division from 1981 to 1988 where he held a number of positions including Director of the Department of Molecular Pharmacology. Dr. Mirabelli received his Ph.D. degree in molecular pharmacology from Baylor College of Medicine.
- Peter H. Reinhart, Ph.D.
Chief Scientific Officer
Dr. Reinhart joined Proteostasis in February 2010. He previously oversaw Neurodegeneration Research at Wyeth Pharmaceuticals and Pfizer, focusing on Alzheimer's disease, Parkinson’s disease, stroke regeneration, and ALS programs. During his six-year tenure there, Dr. Reinhart delivered numerous small molecule as well as biomolecule drug candidates into clinical development. Prior to joining Wyeth, he served as Vice President, Neurodegeneration at Cogent Neuroscience after twelve years as a faculty member at Duke University Medical Center, where he continues to serve as an adjunct professor. Dr. Reinhart is on the Scientific Advisory Board of the Michael J. Fox Foundation for Parkinson's Research, and contributes to numerous government and foundation grant review boards. Dr. Reinhart received a B.Sc. and Ph.D. in Biochemistry from the Australian National University and did his postdoctoral training in Neurobiology at the University of Tuebingen, Germany, and was a research fellow at Brandeis University. He has authored more than 90 publications, and serves as a scientific reviewer for Science, Neuron, Nature Drug Discovery, Journal of Neuroscience, and Molecular Pharmacology.
Pauline Jen Ryan
Senior Vice President, Business Operations
Ms. Ryan joined Proteostasis in September 2008 after consulting to the company for a year in preparation for the Series A round and subsequent company launch. She has over twenty years of business experience in the biotechnology and pharmaceutical industries. Most recently, she was Senior Vice President, Corporate Development and Operations for publicly-traded ImmunoGen, where she was responsible for strategic planning, business development, alliance management, and commercial development, as well as manufacturing operations, supply chain management, and manufacturing collaborations. In eight years there, she negotiated numerous corporate partnerships that generated over $150M in revenue. Her prior experience also includes business development roles at Organogenesis as well as management consulting roles at boutique life sciences consulting firms. Ms. Ryan has an MBA from the Kellogg School of Management at Northwestern University.
- Dan Garza, Ph.D.
Head of Cellular & Molecular Biology
Prior to joining Proteostasis in November 2008, Dr. Garza was an Executive Director in the Department of Functional Genomics and led a Stress Response Pathways Program at the Novartis Institutes for Biomedical Research. Prior to joining Novartis, from 1994 to 2001, he was an Assistant Professor in the Program in Medical Sciences at Florida State University, where he studied genome structure and function as well as steroid hormone signaling in Drosophila. He is an author on over 30 scientific publications. He received his B.S. in Biochemistry from SUNY Stonybrook, his Ph.D. in Molecular Biology from Washington University School of Medicine, St. Louis and was a Helen Hay Whitney post-doctoral fellow in the Department of Developmental Biology at Stanford University Medical School.
- Hui Ge, Ph.D.
Head of Systems Biology
Dr. Ge joined Proteostasis in December 2008. Previously, she led a computational biology lab at the Whitehead Institute for Biomedical Research. Dr. Ge pioneered system-level studies of protein networks and developed predictive models of gene function in organism development and diseases. Her achievements include devising a variety of novel computational approaches for integrating various types of high-throughput biological data. Her research has been published in top scientific journals including Nature, Science, and Cell. She received a B.S. from Beijing University and a Ph.D. from Harvard University.
- J. Steven Jacobsen, Ph.D.
Head of Translational Biology
- Dr. Jacobsen joined Proteostasis in May 2010 after a 22-year career at Pfizer and predecessor companies Wyeth and Lederle. He headed the Alzheimer’s research efforts for 15 years, during which he delivered eight small molecules, vaccines and biologics into development. Dr. Jacobsen is recognized as a pharmaceutical expert in Alzheimer’s disease and is frequently invited to speak at international academic conferences on various discovery, biomarker/translation, and early clinical development programs and has also represented PhRMA (the industry trade group, Pharmaceutical Research and Manufacturers of America) in various meetings on Capitol Hill. He is an author on over 50 publications, serves as an Associate Editor for Current Alzheimer Research, and is an Adjunct Associate Professor at Ohio State University and at the New York University School of Medicine. Dr Jacobsen received his B.S. in Biology and M.S. in Microbiology from Seton Hall University and his Ph.D. in Molecular Genetics and Microbiology from the New Jersey Medical School at the University of Medicine and Dentistry of New Jersey.
Brad Geddes, Ph.D.
Head of Pharmacology
Prior to joining Proteostasis in March of 2009, Dr. Geddes was Senior Director of Drug Discovery at Elixir Pharmaceuticals, Inc. where he was responsible for preclinical development programs focused on metabolic disease, including their ghrelin receptor antagonist program recently partnered with Novartis. Previously, at MDS Proteomics, he was project manager for a $45M collaboration with Cephalon Inc. From 1999 to 2003, Dr. Geddes worked at Millennium Pharmaceuticals, Inc. in the areas of neurodegenerative and metabolic diseases. He is an author on over 25 scientific articles and book chapters. He received both his BSc in Biology and MSc in Neuroendocrinology from the University of Guelph (Canada) and received his Ph.D. in Molecular Neurobiology from the University of Bristol, UK.
- Walter Newman, Ph.D.
Head of External Innovation
- Dr. Newman, in his role at HealthCare Ventures, worked closely with the scientific founders to facilitate the start of Proteostasis Therapeutics, Inc. in early 2007. Dr. Newman has been a Director at HealthCare Ventures since 2006, and, prior to that, has held a series of senior level positions in Cambridge startups, including as the Senior Vice President of R&D and Chief Scientific Officer at Critical Therapeutics and SVP for Research at LeukoSite (and subsequently SVP of Biotherapeutics at Millenium Pharmaceuticals after LeukoSite was acquired by Millennium). Prior to that, Dr Newman had group leadership responsibilities for anti-inflammatory drug discovery at Otsuka Pharmaceuticals and Ortho Pharmaceuticals. Prior to an academic career at the Fred Hutchinson Cancer Research Center in Seattle, Dr. Newman did his doctoral and postdoctoral training in immunology at Columbia University and the Albert Einstein College of Medicine, respectively. He has authored over 80 peer reviewed papers and holds numerous patents.
- Bradley Tait, Ph.D.
Head of Chemistry
Dr. Tait joined Proteostasis in November 2008. He has over 20 years of experience in the pharmaceutical industry at Schering Plough, Parke-Davis and Pfizer, including eight years of drug discovery management. His experience spans multiple therapeutic areas, including infectious disease, CNS, allergy/respiratory, inflammation and cardiovascular. He has delivered seventeen compounds into clinical development and contributed to 20 patents and 25 publications. Dr. Tait received a Ph.D. from Wayne State University and did post-doctoral work at Yale University.
|
|
